Olanzapine was an effective additional antiemetic for children and young people undergoing highly emetogenic chemotherapy.

Review of Perkin MR, Bahnson HT, Logan K, et al . Association of early introduction of solids with infant sleep. A secondary analysis of a randomized clinical trial. JAMA Pediatr 2018;172:e180739.\n\nSetting: Tertiary hospital in New Delhi, India.\n\nPatients: Children aged between 5 and 18 years, weighing over 15 kg, who were scheduled to receive their first cycle of highly emetogenic chemotherapy.\n\nIntervention: Olanzapine (0.14 mg/kg orally, once daily, rounded to the nearest 2.5 mg, up to a maximum of 10 mg) during treatment and for 3 days afterwards, in addition to a standard antiemetic regimen (ondansetron, dexamethasone and aprepitant) compared with standard antiemetic alone.\n\nOutcomes: Number of patients with complete response to antiemetics with no vomiting and no severe nausea requiring rescue medication, assessed by hospital investigators during inpatient chemotherapy and reported …